Upadacitinib Safe and Effective for Atopic Dermatitis in Adolescents at 76 Weeks: RCT Analysis
Upadacitinib (15 and 30 mg) was evaluated in adolescents with moderate to severe AD aged 12 to 17 years, with and without topical corticosteroids.
Nirsevimab-alip Gets Unanimous ACIP Recommendation to Prevent RSV in Neonates, Infants
The ACIP was unanimous in its recommendation for routine use of nirsevimab-alip to prevent RSV LRTD in newborns and young infants during their first RSV season.
FDA Approves Nirsevimab-alip Injection to Prevent RSV in Neonates, Infants
FDA approval of the monoclonal antibody against RSV follows the unanimous vote from the agency's Antimicrobial Drugs Advisory Committee.
